New inhaler treatment aims to boost oxygen in COPD lungs

NCT ID NCT07037836

Recruiting now Disease control Sponsor: Bastiaan Driehuys Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether an inhaled drug called treprostinil (Tyvaso) can improve oxygen delivery in the lungs of people with COPD who have low blood oxygen. Ten adults will use the nebulizer four times daily for four weeks, starting at a low dose and increasing as tolerated. Researchers will use special MRI scans to measure changes in lung blood flow and oxygen exchange before and after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Inhaled treprostinil (Tyvaso nebulizer)
What this could lead to: If it works, this could point toward a new treatment to improve oxygen delivery and lung function in COPD patients with low blood oxygen.
What could go wrong: This is a very small, early-phase trial with only 10 participants, so results may not apply to everyone. The drug may cause side effects and may not show clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset Hypoxia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE) HYPOXEMIA

Contacts and locations

Locations

Duke Asthma Allergy and Airway Center
RECRUITING

Durham, North Carolina, 27705, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.